About us

VISION & MISSION

With the vision “New Tools Lead to a New World,” EditForce is committed to developing pentatricopeptide repeat (PPR) proteins as the novel, globally standardized, and versatile DNA/RNA editing tools to be used in a variety of species, to bring innovation to pharmaceutical, agricultural, and
biomanufacturing industries.

We strive for innovation to transform impossible into possible, difficulty into possibility, and inspiration into reality.

Overview

Name EditForce, Inc.
Established May 15, 2015
Capital 90 million yen
President and CEO Takashi Ono
Head office 4F Fukuoka Tenjin Fukoku Seimei Bldg. 1-9-17, Tenjin, Chuo-ku, Fukuoka. 810-0001 JAPAN
Fukuoka Laboratory West Zone 5 #430, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395 JAPAN
TEL+81-92-802-4935
Tokyo Office Shiodome Bldg., 3rd Fl.1-2-20 Kaigan, Minato-ku, Tokyo, 105-0022 JAPAN
TEL+81-3-6721-8883
Business area Application of DNA/ RNA manipulation technology to reagents, pharmaceuticals, agriculture, chemical production etc.
Investors KISCO Ltd., The University of Tokyo Edge Capital Co., Ltd., QB Capital, LLC, Japan Science and Technology Agency, ITOCHU Technology Ventures, Inc., Newton Biocapital SA, K4 Ventures GK (The Kansai Electric Power Group)

(As of August 1st, 2020 )

Access

Fukuoka Laboratory

West Zone 5 #430, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395 JAPAN

TEL+81-92-802-4935

Tokyo Office

Shiodome Bldg., 3rd Fl.1-2-20 Kaigan, Minato-ku, Tokyo, 105-0022 JAPAN

TEL+81-3-6721-8883

Team

President, CEO
Takashi Ono, Ph.D.

Takashi Ono

EditForce was established in 2015. Since then, we have put our effort on the development of PPR proteins as the novel DNA/RNA editing tools, which are to be applied in a variety of fields such as pharmaceuticals, agriculture, and biomanufacturing.
DNA/RNA editing is an expanding field of technology as it is one of the key measures in solving the global issues including health, food, and environment.
Our PPR technology, distinguished from other conventional tools, enables editing of RNA in addition to DNA. As we have reached the stage of putting it into practice, we are eager to collaborate with specialists in each academic/industrial field in need for such novel technology.

To start with, we focus on the field of pharmaceuticals to discover new agents with new mechanisms of action.

Director, CTO
Yusuke Yagi, Ph.D.

Yusuke Yagi

Our bodies are based on the communications between massive cell populations, and individual cells are controlled by a program called a genome and genome-derived software called RNA. Although genomic information has been decoded via the efforts of many researchers, we still have no means to manipulate cells. We believe that if it becomes possible to manipulate cellular programs freely, the relevant technology would significantly change medical treatments and agriculture. Genome editing technologies were considered a breakthrough in this field, followed only after a few years by a great change in the methods of biological research. We possess novel RNA manipulation technology, and we are convinced that this technology will enable the manipulation of not only the genome but also RNAs, which are more complex, and lead to the creation of a new industry and future.

Director,
Osamu Nakanishi, Ph.D.

Osamu Nakanishi

New modalities called nucleic acid medicines including antisense oligonucleotides (ASO) and siRNAs are actually being used clinically as therapeutic agents for genetic diseases, and research for new therapeutics targeting mRNA has started in earnest. Our PPR technology is not only limited to RNA degradation (knockdown) and splicing control that are possible by 1st-generation RNA-targeted agents such as ASO and siRNA, but also possible to enhance translation of mRNA and sequence repair by base editing. Therefore, it has the potential to be the next-generation RNA-targeted drug that can be applied to a wider range of genetic diseases. Furthermore, when combined with gene delivery systems such as AAV, a persistent therapeutic effect can be expected with a single dosing. We would like to develop Japan-originated new medicines using this Japan-originated PPR technology.

Outside director

Atsushi Usami
The University of Tokyo Edge Capital Co., Ltd, Partner
Teruyuki Fukuda
KISCO LTD. Director & Executive Officer
Koji Abe
ITOCHU Technology Ventures, Inc., Vice President
Toshiyuki Mori
Newton Biocapital SA, Investment partner

Auditor

Yasushi Kojima
Full-time auditor
Tomotaka Goji
The University of Tokyo Edge Capital Co., Ltd, Managing Partner and President
Yasunobu Akimitsu
KISCO LTD. Finance and Accounting Depart, General Manager

Scientific Advisory Board

Takahiro Nakamura
Prof., Genome Chemistry and Engineering, Kyushu Univ.

Science advisor

Takashi Yamamoto
Prof., Faculty of Science, Hiroshima Univ.

Publication List